Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline

Nitin R. Patel () and Suresh Ankolekar ()
Additional contact information
Nitin R. Patel: Cytel Inc.
Suresh Ankolekar: Maastricht School of Management

Chapter Chapter 11 in Optimization of Pharmaceutical R&D Programs and Portfolios, 2015, pp 181-200 from Springer

Abstract: Abstract In this chapter we describe a mathematical approach to maximize the Expected Net Present Value (ENPV) of a portfolio over a planning horizon by determining the optimal designs of Phase 3 (Ph3) trials for a given budget. The model is formulated as a Stochastic Integer Programming (SIP) model that incorporates uncertainty regarding availability of drugs in the pipeline. The SIP model provides an optimal policy that specifies the optimal design for each drug for every possible scenario of availability of future drugs for Ph3 trials. It optimizes the trade-off between committing budget to drugs available for Ph3 funding at any point in time and preserving budget for drugs in the development pipeline that will need funding in the future. Optimizing this trade-off is challenging because it is uncertain which drugs will need funding in the future as they may fail to progress to Ph3. This important trade-off is not handled in a consistent, quantitative way in portfolio budgeting models used in practice today. We have also developed a simulation model to assess the technical, regulatory, and commercial risk of the optimal budget allocation policy. We show how our models can be used for dynamic re-optimization of the portfolio when changes in the internal and external environment occur and as new information becomes available. This capability will enable rapid, frequent, and consistent realignment of the strategy to optimize future use of the budget available for reallocation. We illustrate our approach using an example that shows how our models can be used to decide on the best budget level to meet a target Return on Investment (ROI) and to evaluate risk of the optimal allocation strategy associated with this budget level. We have shown how these models can be used to answer important what-if questions such as those that arise when in-licensing or out-licensing drug development.

Keywords: Portfolio optimization; Budget allocation; Decision analysis; Stochastic integer programming; Risk; Re-optimizing budget allocation; In-licensing; Out-licensing (search for similar items in EconPapers)
Date: 2015
References: Add references at CitEc
Citations: View citations in EconPapers (2)

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-09075-7_11

Ordering information: This item can be ordered from
http://www.springer.com/9783319090757

DOI: 10.1007/978-3-319-09075-7_11

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().